News Agency
Men's Weekly

Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO

  • Written by PR Newswire

HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The principal investigators of the study are Prof. Bai...

Read more: Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of...

How Labour Hire Supports Sydney and Gold Coast Businesses

Labour hire has transformed from a simple stopgap measure into one of the most strategically valuable workforce solutions for businesses right across Sydney and the Gold Coast. As various industries grow, adapt to punishing seasonal demand, or suddenly find themselves... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion